Use and cost comparison of clobazam to other antiepileptic drugs for treatment of Lennox-Gastaut syndrome. by François, Clément et al.
UCLA
UCLA Previously Published Works
Title



















eScholarship.org Powered by the California Digital Library
University of California
TRANSFERRED ARTICLE
Use and cost comparison of clobazam to other antiepileptic drugs for treatment
of Lennox-Gastaut syndrome
Clément Françoisa, JohnM. Sternb, Augustina Ogbonnayac, Tasneem Lokhandwala c, Pamela Landsman-Blumbergc,
Amy Duhigc, Vivienne Shena and Robin Tanc
aHealth Economics and Outcomes Research, Lundbeck, LLC, Deerfield, IL, USA; bDepartment of Neurology, University of California, Los
Angeles, Los Angeles, CA, USA; cScientific Consulting, Xcenda, LLC, Palm Harbor, FL, USA
ABSTRACT
Background: Lennox-Gastaut syndrome (LGS) is a severe form of childhood-onset epilepsy
associated with serious injuries due to frequent and severe seizures. Of the antiepileptic drugs
(AEDs) approved for LGS, clobazam is a more recent market entrant, having been approved in
October 2011. Recent AED budget impact and cost-effectiveness analyses for LGS suggest that
adding clobazam to a health plan formulary may result in decreased medical costs; however,
research on clinical and economic outcomes and treatment patterns with these AED treatments
in LGS is limited.
Objectives: To compare the baseline characteristics and treatment patterns of new initiators of
clobazam and other AEDs among LGS patients and compare healthcare utilization and costs
before and after clobazam initiation among LGS patients.
Methods: A retrospective study of probable LGS patients was conducted using the MarketScan®
Commercial, Medicare Supplemental, and Medicaid databases (10/1/2010-3/31/2014).
Results: In the Commercial/Medicare Supplemental population, clobazam users were younger,
had fewer comorbidities, and more prior AED use than non-clobazam users. In the 12 months
pre-treatment initiation, clobazam users had significantly more seizure-related inpatient stays and
outpatient visits and higher total seizure-related (P < 0.001) and all-cause (P < 0.001) costs than
non-clobazam users. Among clobazam users, when compared to the 12 months pre-clobazam
initiation, seizure-related medical utilization and costs were lower in the 12 months post-cloba-
zam initiation (P = 0.004). Total all-cause (P < 0.001) and seizure-related (P = 0.029) costs
increased post-clobazam initiation mainly due to the increase in outpatient pharmacy costs.
Similar results were observed in the Medicaid population.
Conclusions: Baseline results suggest a prescribing preference for clobazam in severe LGS
patients. Clobazam users had a reduction in seizure-related medical utilization and costs after
clobazam initiation. The improvement in medical costs mostly offset the higher prescription costs
following clobazam initiation.
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Lennox-Gastaut syndrome (LGS) is a severe type of
epilepsy with onset in childhood and characterized
by intellectual disability, specific electroencephalo-
graphic abnormalities, and frequent generalized-
onset or sometimes focal-onset seizures [1]. LGS typi-
cally develops before eight years of age, with occur-
rence rates peaking between three and five years of
age; however, late cases in early adulthood have also
been reported [1]. Estimated to account for 1–10% of
all childhood epilepsies, LGS has a mortality rate
between 4% and 7% in patients younger than
11 years of age [2–4].
LGS can have a major physical impact due to
frequent and severe seizures that increase the
likelihood of fall-related injuries. Seizures during the
childhood development stage can halt cognitive and
social development and lead to behavioral impair-
ment [1,5]. Cognitive impairment is seen in 75–95%
of patients five years after condition onset, and 90%
will eventually become intellectually disabled [5,6].
Additionally, LGS has a significant impact on the
health-related quality of life of not only the patient
but also their caregiver [7].
Six antiepileptic drugs (AEDs) have been approved to
date by the United States Food and Drug
Administration (FDA) for the treatment of LGS: cloba-
zam; clonazepam; felbamate; lamotrigine; topiramate;
and rufinamide. Valproate and clorazepate, which are
not approved by the FDA for LGS treatment, are
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routinely used in these patients [8,9]. Of the approved
drugs, clobazam is a more recent market entrant, hav-
ing been approved in October 2011 for use as an
adjunctive treatment for seizures associated with LGS
in adults and children two years of age and older.
Clobazam has demonstrated both short- and long-
term efficacy in children, adolescents, and adults, and is
well tolerated across all ages [10]. Recent AED budget
impact and cost-effectiveness analyses for LGS suggest
that adding clobazam to a health plan formulary may
have a positive overall budget impact through
decreased medical costs, as clobazam has been proven
efficacious in the treatment of drop seizures, which are
a major cause of morbidity and healthcare utilization
among these patients [11,12]. Clobazam has specifically
been shown to be more effective and less costly than
rufinamide over a two-year period [11].
Currently, there is limited research on clinical and
economic outcomes and a lack of information on treat-
ment patterns with the aforementioned AED treat-
ments in LGS. Therefore, this study had two
objectives: (1) to describe the baseline characteristics
and treatment patterns of LGS patients treated with
clobazam compared to other AED treatments; and (2)
to compare healthcare resource utilization and costs
before and after treatment among clobazam users.
Methods
Study design
This retrospective longitudinal cohort study used admin-
istrative claims data with dates of service from 1 October
2010 through 31 March 2014. The date treatment of
interest initiated was set to be the index date. The study
enrollment period was between 1 October 2011 and 30
September 2013, allowing a 12-month pre-treatment
initiation period (i.e., pre-index) and a minimum six-
month post-treatment initiation (i.e., post-index) period.
Data source
This study was conducted using three Truven Health
MarketScan® claims databases [12]: the Commercial
Claims and Encounters Database (Commercial); the
Medicare Supplemental and Coordination of Benefits
Database (Medicare Supplemental); and the Medicaid
Multi-state Database (Medicaid). The Commercial data-
base consists of employer- and health plan-sourced
data containing medical and drug claims for over 40
million individuals annually. The Medicare
Supplemental database contains the medical and pre-
scription claims of Medicare-eligible persons with
supplemental insurance offered by their former
employers. There are approximately 4.3 million enrol-
lees annually included in the database. For the pur-
poses of these analyses, the Commercial and Medicare
Supplemental databases were combined and a single
unique identifier allows for patients to be followed as
they move from a Commercial payer to Medicare. The
Medicaid database contains the medical and prescrip-
tion drug experience of Medicaid enrollees in both fee-
for-service and managed-care plans pooled from 10 to
13 states annually.
Patient identification
Criteria used to identify patients with LGS were based
on a previously published algorithm [13] and clinical
input (John M. Stern and Vivienne Shen), and are as
follows: (1) ≥2 medical claims with a diagnosis of gen-
eralized convulsive (International Classification of
Diseases, Ninth Revision, Clinical Modification [ICD-9-
CM: 345.1x]) or non-convulsive epilepsy (ICD-9-CM:
345.0x) that are ≥30 days apart, or ≥1 medical claim
with a diagnosis of generalized convulsive epilepsy
(ICD-9-CM: 345.1x) and ≥1 medical claim with a diag-
nosis of non-convulsive epilepsy (ICD-9-CM: 345.0x) that
are ≥30 days apart; (2) ≥1 of the epilepsy diagnosis
codes had to be in the primary position; (3) ≥1 medical
claim with a diagnosis for developmental disorder or
cognitive impairment (ICD-9-CM: 299.80, 299.81, 299.90,
299.91, 294.8x, 294.9x, 315.39, 315.4x, 315.5x, 315.8x,
315.9x, 316.xx, 317.xx, 318.0x, 318.1x, 318.2x, 319.xx,
348.3x, 348.89, 780.97, and 783.4x) in any position dur-
ing the enrollment window.
Based on the AED treatment initiated during the
enrollment window and after the first evidence of LGS
diagnosis, patients were further classified into one of
two mutually exclusive treatment groups: clobazam or
non-clobazam. Patients in the clobazam cohort initiated
treatment with clobazam, and may have received prior
treatment with another AED. The date of the first clo-
bazam prescription fill was deemed the index date.
Patients in the non-clobazam cohort initiated treatment
with another AED (clonazepam, felbamate, lamotrigine,
rufinamide, topiramate, valproate, or clorazepate). To
qualify as the index prescription, the patient had to be
naïve to that particular AED (i.e., have no other pre-
scription claims for that AED in the prior 12 months);
otherwise, the subsequent AED prescription was evalu-
ated similarly. Lastly, patients must have continuous
enrollment in medical and pharmacy benefits for
≥12 months prior to and ≥6 months after the index
date. For the pre- and post-clobazam healthcare
resource utilization and cost comparison, clobazam
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patients had to have ≥12 months of post-index contin-
uous enrollment. Patients were excluded if they did not
have a qualifying AED prescription during the enroll-
ment window or if they were dually eligible for both
Medicare and Medicaid, as prescription claims were not
available for these patients.
Study measures
Demographic and clinical characteristics
Demographic characteristics, including age, gender,
race (Medicaid only), geographic region (Commercial/
Medicare Supplemental only), urban/rural, plan type
(Commercial/Medicare Supplemental only), payer type
(Commercial/Medicare Supplemental only), capitation,
reason for eligibility (Medicaid only), length of follow-
up, and year of index date, were measured on index for
each patient. Pre-index clinical characteristics included
use of medication classes (other seizure medications,
anxiolytics, antipsychotics, and hypnotics), number of
unique medication classes used, number of AED drugs
of interest, and comorbidities.
Healthcare resource utilization and costs
Healthcare resource utilization and costs were con-
ducted from the perspective of a private or governmen-
tal insurance plan in the United States. Per-patient all-
cause and seizure-related healthcare resource utiliza-
tion and their associated costs were reported by treat-
ment setting (e.g., inpatient, emergency room [ER],
physician office, laboratory, radiology, other outpatient,
and pharmacy) during the pre-index period and also for
the clobazam cohort during the post-index period. All-
cause resource utilization included all medical and
pharmacy services for any reason during the time per-
iod of interest. Medical resource utilization was deemed
to be seizure-related if the primary ICD-9-CM diagnosis
code on a claim was 345.0x–345.9x, and seizure-related
pharmacy services included all prescriptions for the
AEDs of interest and other seizure-related medications
(Table 1). All-cause healthcare costs were costs asso-
ciated with all utilizations, while seizure-related health-
care costs were costs for all seizure-related utilizations.
Costs reflected all payments made to providers of care
from both the plan (plan and coordination of benefits)
and the patient (copayment, coinsurance, deductible).
All costs were adjusted to 2014 United States dollars
(USD) using the medical care component of the Bureau
of Labor Statistics’ Consumer Price Index.
Treatment patterns
Treatment patterns were assessed for both study
cohorts during the post-index period and included the
number of index AED prescription claims, total days on
index drug and all AEDs, changes to the index treat-
ment (i.e., augmentation, switching, discontinuation),
and discontinuation from all AEDs. Augmentation was
defined as a prescription fill for an alternative AED
treatment (one of the seven non-index AEDs) while
continuing to fill prescriptions for the index AED.
Switching was defined as a prescription fill for a new
AED that was different from the index agent, with no
further prescription fills for the index AED.
Discontinuation from index treatment and from all
AEDs was defined as a >30-day period without evi-
dence of having the index AED and or any AEDs on
hand respectively.
Statistical analyses
Separate analyses were conducted for the combined
Commercial and Medicare Supplemental and Medicaid
populations.
Table 1. Antiseizure medications.
Medication/medication class Generic name (brand)
AMPA receptor antagonist Perampanel (Fycompa)
SVP2a binder Levetiracetam (Keppra, Keppra XL)
Carbonic anhydrase inhibitor Acetazolamide (Diamox)
Sodium channel inhibitor Carbamazepine (Tegretol), Eslicarbazepine (Aptiom), Oxcarbazepine (Trileptal), Rufinamide (Banzel)
GABA analogues Gabapentin (Neurontin), Pregabalin (Lyrica), Progabide (Gabrene), Vigabatrin (Sabril)
GABA reuptake inhibitors Tiagabine (Gabitril)
K-channel opener Ezogabine/Retigabine (Potiga)
NMDA receptor blockers Felbamate (Felbatol), Sodium Channel Modulators, Lacosamide (Vimpat), Lamotrigine (Lamictal), Phenytoin (Dilantin)
T-type calcium channel Ethosuximide (Zarontin), Methsuximide (Celontin)
Sulfamate-substituted
monosaccharides
Topiramate (Topamax, Topamax ER, Qudexy XR)
Sodium channel Zonisamide (Zonegran)
Valproic acid Divalproex Sodium (Depakote), Valproic Acid (Depakene)
Barbiturates Phenobarbital, Primidone (Mysoline)
Benzodiazepines Clobazam (Onfi), Clonazepam (Klonopin, Epitril, Rivotril), Clorazepate Dipotassium (Tranxene), Diazepam (Valium,
Diastat), Lorazepam (Ativan)
Notes: GABA – gamma aminobutyric acid; NMDA – N-methyl-D-aspartate; SVP2a – synaptic vesicle protein 2A.
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Clobazam vs non-clobazam cohorts
Descriptive statistics (percentages, means, medians,
standard deviations) were used to describe the baseline
characteristics of the clobazam and non-clobazam
cohorts. Statistical comparison of baseline measures
was conducted using chi-squared tests for categorical
measures and Student’s t-tests or Mann-Whitney tests
for continuous measures, as appropriate to the under-
lying distribution. To create comparability of the base-
line demographic and clinical characteristics of
clobazam and non-clobazam users for treatment pat-
tern comparisons, standardized mortality ratio weight-
ing, a propensity score (PS) technique, was employed in
order to ameliorate selection bias prior to comparison
of outcomes [14]. PS for each patient was estimated
using a logistic regression model that included patients’
baseline characteristics as the independent variables
and treatment as the dependent variable. Weights
were computed as follows: 1 (PS/PS) for clobazam
users and PS/(1 − PS) for the non-clobazam users.
As baseline characteristics between the clobazam
and non-clobazam cohorts remained unbalanced, for
treatment patterns during the post-index period,
descriptive statistics were presented for the clobazam
and non-clobazam cohorts, and no statistical compar-
ison was performed.
Healthcare resource utilization and costs pre- and
post-clobazam initiation
Among the clobazam cohort, healthcare resource utili-
zation, and costs pre- and post-treatment initiation
were compared. Statistical differences in categorical
measures were analyzed using McNemar’s tests, count




A total of 44,921 Commercial/Medicare
Supplemental patients and 19,110 Medicaid patients
with evidence of epilepsy were identified during the
enrollment window (Figure 1). After applying the
study inclusion and exclusion criteria, the final
Commercial/Medicare population consisted of 1974
LGS patients, with 590 (29.9%) clobazam users and
1384 (70.1%) non-clobazam users. The Medicaid
population consisted of 2012 LGS patients, with
647 (32.2%) clobazam users and 1365 (67.8%) non-
clobazam users. The average age of the Commercial/
Medicare Supplemental population was 26.1 years
(standard deviation [SD]: 21.9) and 50.9% were
males (Table 2). Patients in the clobazam cohort
were younger (14.8 ± 12.5 vs 31.0 ± 23.2,
P < 0.001) and a higher proportion were males
compared to the non-clobazam cohort (54.6% vs
49.3%, P = 0.034). The average age of the Medicaid
population was 20.7 (±16.8) years old and 51.6%
were males (Table 3). Clobazam users were again
younger compared to non-clobazam users
(13.7 ± 11.4 vs 24.1 ± 17.9, P < 0.001).
Baseline clinical characteristics
Among the Commercial/Medicare Supplemental
patients, compared to the non-clobazam cohort,
higher proportions of the clobazam cohort had
pre-index prescription fills for AEDs and other sei-
zure-related medications (95.8% vs 77.1%, P < 0.001)
and anxiolytics (35.1% vs 28.8%, P = 0.006), and a
lower proportion had pre-index prescription fills for
antipsychotics (10.3% vs 14.8%, P = 0.008) (Table 2).
The clobazam cohort also had evidence of using a
higher number of unique AED agents (1.7 ± 1.1 vs
0.5 ± 0.7, P < 0.001) and a lower number of non-AED
prescription classes (5.8 ± 4.9 vs 6.6 ± 6.2, P = 0.002)
prior to index. Significant differences were observed
in the majority of comorbidities assessed, with the
prevalence being lower in the clobazam cohort than
in the non-clobazam cohort, with the following
exceptions: tuberous sclerosis (2.7% vs 0.3%;
P < 0.001), cortical dysplasia (3.1% vs 1.2%,
P = 0.005), intellectual disorder (25.1% vs 11.3%,
P < 0.001), eating disorder (17.8% vs 5.8%,
P < 0.001), and digestive/bowel disorder (39.0% vs
33.2%, P = 0.014).
Among LGS Medicaid patients, baseline use of AEDs,
other seizure-related medications, and non-AEDs was
similar to that observed in the Commercial/Medicare
Supplemental patients, with the exception that the
clobazam cohort had claims for a similar number of
pre-index non-AED prescription classes as the non-clo-
bazam cohort. Baseline comorbidity differences were
similar to the Commercial/Medicare Supplemental
population with one exception: there was no significant
difference in the baseline rates of digestive/bowel dis-
order between the cohorts.
Baseline seizure-related resource utilization and
costs
Commercial/Medicare Supplemental clobazam users had
higher pre-index seizure-related resource utilization and
associated costs compared to non-clobazam users
(Table 4). Higher proportions of clobazam users had at
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least one seizure-related hospitalization (36.8% vs 27.5%,
P < 0.001), physician office visit (94.6% vs 78.1%,
P < 0.001), neurologist visit (58.8% vs 52.7%, P = 0.012),
laboratory visit (43.1% vs 19.8%, P < 0.001), and other
outpatient visit (67.5% vs 46.2%, P < 0.001). Clobazam
users also had higher average seizure-related total inpa-
tient length of stay (LOS) (2.6 ± 7.6 days vs 1.4 ± 4.7 days,
P = 0.001) and higher average numbers of seizure-related
visits by setting of care than non-clobazam users.
The higher seizure-related resource utilization among
the clobazam cohort led to higher average annual seizure-
related costs over the pre-index period. Average annual
pre-index seizure-related total ($33,478 ± $58,431 vs
$12,709 ± $36,420, P < 0.001), medical
($24,066 ± $56,142 vs $10,563 ± $35,194, P < 0.001), and
prescription ($9411 ± $12,416 vs $2146 ± $5596,
P < 0.001) costs were significantly higher for clobazam
users compared to non-clobazam users. Pre-index aver-
agemedical costs by setting of care among patients in the
clobazam cohort were two to four times greater than
those of the non-clobazam cohort.
Medicaid clobazam users also had higher seizure-
related resource utilization, on average, over the 12-
month pre-index period compared to non-clobazam
users (Table 4), with two exceptions. Unlike the
Commercial/Medicare Supplemental patients, no sig-
nificant differences were observed between the pro-
portion of patients with a seizure-related neurologist
visit or in the number of primary care provider (PCP)
visits. Overall, pre-index cost differences were similar
to the Commercial/Medicare Supplemental popula-
tion, except there were no significant differences
between the clobazam and non-clobazam cohorts
in the cost of seizure-related neurologist visits.
Evidence of epilepsy during enrollment window
10/1/11–9/30/13
n=44,921 (100%)
Evidence of developmental disorder/cognitive
impairment during enrollment window
n=11,121 (24.8%)
Final Commercial and Medicare sample
n=1,974 (4.4%)













Evidence of developmental disorder/cognitive
impairment during enrollment window
n=10,221 (53.5%)
≥1 prescription fill for any of the 8 AEDs of
interest during enrollment window
n=8,569 (19.1%)
≥1 prescription fill for any of the 8 AEDs of
interest during enrollment window
n=4,767 (24.9%)
Continuous enrollment in medical and pharmacy
benefits ≥12 months prior to index datea
n=6,212 (13.8%)
Continuous enrollment in medical and pharmacy
benefits ≥12 months prior to index datea
n=3,830 (20.0%)
Continuous enrollment in medical and pharmacy
benefits ≥6 months after index datea
n=7,298 (16.2%)
Continuous enrollment in medical and pharmacy
benefits ≥6 months after index datea
n=4,053 (21.2%)












Commercial and Medicare Patients Medicaid Patients
Figure 1. Non-mutually exclusive sample attrition commercial and medicare patients.
Notes: AED – antiepileptic drug. a Continuous enrollment could only be verified for patients with an AED prescription fill within the
enrollment window, as only these patients were assigned an index date. b Not mutually exclusive.
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Table 2. Baseline demographic and clinical characteristics of commercial/Medicare Supplemental patients.
Clobazam Non-clobazam
N = 590 N = 1384 P-valuea
Demographic characteristics
Age in years, mean (SD) 14.8 (12.5) 31.0 (23.2) <0.001
Age group in years, n (%)
0–5 117 19.8% 116 8.4% <0.001
6–12 221 37.5% 266 19.2%
13–17 84 14.2% 165 11.9%
18–34 120 20.3% 314 22.7%
35–44 21 3.6% 117 8.5%
45–54 15 2.5% 129 9.3%
55–64 8 1.4% 131 9.5%
65+ 4 0.7% 146 10.5%
Males, n (%) 322 54.6% 683 49.3% 0.034
Geographic region, n (%)
Northeast 138 23.4% 309 22.3% 0.41
North central 139 23.6% 280 20.2%
South 179 30.3% 461 33.3%
West 118 20.0% 290 21.0%
Unknown 16 2.7% 44 3.2%
Urban, n (%) 529 89.7% 1224 88.4% 0.431
Plan type, n (%)
FFS 11 1.9% 97 7.0% <0.001
EPO/PPO 379 64.2% 891 64.4%
HMO 73 12.4% 164 11.8%
POS 49 8.3% 76 5.5%
CDHP/HDHP 57 9.7% 112 8.1%
Unknown 21 3.6% 44 3.2%
Payer type, n (%)
Commercial 585 99.2% 1223 88.4% <0.001
Medicare 5 0.8% 161 11.6%
Capitation, n (%)
Yes 36 6.1% 98 7.1% 0.429
No 554 93.9% 1286 92.9%
Index year, n (%)
2011 2 0.3% 122 8.8% <0.001
2012 421 71.4% 737 53.3%
2013 167 28.3% 525 37.9%
Clinical characteristics
Baseline medication classes,b n (%)
AEDs and other seizure-related medications 565 95.8% 1067 77. 1% <0.001
Benzodiazepines 364 61.7% 289 20.9% <0.001
NMDA receptor blockers 304 51.5% 361 26.1% <0.001
SVP2a binder 268 45.4% 595 43.0% 0.319
Valproic acid 240 40.7% 170 12.3% <0.0001
Sodium channel inhibitor 192 32.5% 205 14.8% <0.001
Sulfamate-substituted monosaccharide 139 23.6% 122 8.8% <0.001
Zonisamide 105 17.8% 100 7.2% <0.001
GABA analogues 51 8.6% 131 9.5% 0.564
T-type calcium channel 36 6.1% 58 4.2% 0.068
Number of unique prescription classes (non-AEDs), mean (SD) 5.8 (4.9) 6.6 (6.2) 0.002
Number of pre-index AED drugs of interest, mean (SD) 1.7 (1.1) 0.5 (0.7) <0.001
Baseline comorbidities,c n (%)
Pain 221 37.5% 797 57.6% <0.001
Any digestive/bowel disorder 230 39.0% 460 33.2% 0.014
Constipation 100 17.0% 143 10.3% <0.001
Psychosis 142 24.1% 516 37.3% <0.001
Migraine/headache 54 9.2% 377 27.2% <0.001
Intellectual disorder 148 25.1% 156 11.3% <0.001
Mild 13 2.2% 27 2.0% 0.716
Moderate 14 2.4% 26 1.9% 0.476
Severe/profound 58 9.8% 46 3.3% <0.001
Other 101 17.1% 100 7.2% <0.001
Anxiety 35 5.9% 289 20.9% <0.001
Depression 25 4.2% 289 20.9% <0.001
Behavioral disorder 114 19.3% 235 17.0% 0.212
Eating disorder 105 17.8% 80 5.8% <0.0001
Sleep disorder 93 15.8% 238 17.2% 0.435
(Continued )
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Table 2. (Continued).
Clobazam Non-clobazam
N = 590 N = 1384 P-valuea
Walking/gait impairment 77 13.1% 160 11.6% 0.351
Cognitive disorder 42 7.1% 213 15.4% <0.001
Stroke/TIA 9 1.5% 179 12.9% <0.001
Arthritis 9 1.5% 157 11.3% <0.001
ADHD 44 7.5% 96 6.9% 0.680
Obesity 7 1.2% 87 6.3% <0.001
Coronary heart disease 3 0.5% 82 5.9% <0.001
Notes: ADHD – attention deficit hyperactivity disorder; AED – antiepileptic drug; CDHP – consumer-driven health plan; EPO – exclusive provider organization;
FFS – fee-for-service; GABA – gamma aminobutyric acid; GI – gastrointestinal; GP – general practitioner; HDHP – high-deductible health plan; HMO –
health maintenance organization; NMDA – N-methyl-D-aspartate; POS – point of service; PPO – preferred provider organization; SD – standard deviation;
SVP2a – synaptic vesicle protein 2A; TIA – transient ischemic attack.
a P < 0.05. P-values were obtained using Chi-square tests for categorical variables and t-tests for continuous variables. Fisher’s exact test was used where Chi-
square test was not valid due to cells having fewer than expected counts.
b Less than 5% of patients in both cohorts received T-type calcium channel, GABA reuptake inhibitor, barbiturate, carbonic anhydrase inhibitor, and
K-channel opener.
c Less than 5% of patients in both cohorts had a diagnosis of cortical dysplasia, tuberous sclerosis, brain lesions, heart failure, and chronic renal disease.
Bold text indicates a statistically significant difference with a p-value < 0.05.
Table 3. Baseline demographic and clinical characteristics of Medicaid patients.
Clobazam Non-clobazam
N = 647 N = 1365 P-valuea
Demographic characteristics
Age in years, mean (SD) 13.7 (11.4) 24.1 (17.9) <0.001
Age group in years, n (%)
0–5 165 25.5% 208 15.2% <0.001
6–12 206 31.8% 267 19.6%
13–17 101 15.6% 157 11.5%
18–34 134 20.7% 342 25.1%
35–44 21 3.2% 141 10.3%
45–54 12 1.9% 144 10.5%
55–64 8 1.2% 106 7.8%
Males, n (%) 331 51.2% 707 51.8% 0.790
Race, n (%)
White 348 53.8% 691 50.6% <0.001
Black 80 12.4% 307 22.5%
Hispanic 35 5.4% 48 3.5%
Other/unknown 184 28.4% 319 23.4%
Capitation, n (%)
Yes 183 28.3% 450 33.0% 0.035
No 464 71.7% 915 67.0%
Reason for Medicaid eligibility, n (%)
Blind/disabled individual 531 82.1% 960 70.3% <0.001
Child (not of unemployed adult/not foster care) 73 11.3% 207 15.2%
Otherb 43 6.6% 198 14.5%
Index year, n (%)
2011 2 0.3% 133 9.7% <0.001
2012 478 73.9% 846 62.0%
2013 167 25.8% 386 28.3%
Clinical characteristics
Developmental and cognitive disorders, n (%) 597 92.3% 1130 82.8% <0.001
Number of unique diagnoses, mean (SD) 3.0 (2.0) 2.0 (1.7) <0.001
Baseline medication classes,c n (%)
AEDs and other seizure-related medications 633 97.8% 1116 81.8% <0.001
Benzodiazepine 429 66.3% 404 29.6% <0.001
NMDA receptor blocker 310 47.9% 384 28.1% <0.001
SVP2a binder 306 47.3% 568 41.6% 0.016
Valproic acid 236 36.5% 209 15.3% <0.001
Sodium channel inhibitor 217 33.5% 289 21.2% <0.001
Sulfamate-substituted monosaccharide 176 27.2% 158 11.6% <0.001
Zonisamide 146 22.6% 107 7.8% <0.001
GABA analogue 49 7.6% 136 10.0% 0.083
Anxiolytics 233 36.0% 401 29.4% 0.003
Antipsychotics 93 14.4% 329 24.1% <0.001
Hypnotics 116 17.9% 211 15.5% 0.161
Number of unique prescription classes (non-AEDs), mean (SD) 7.6 (5.9) 7.8 (6.9) 0.444
Number of pre-index AED drugs of interest, mean (SD) 1.7 (1.1) 0.5 (0.7) <0.001
Baseline comorbidities,d n (%)
(Continued )
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Table 3. (Continued).
Clobazam Non-clobazam
N = 647 N = 1365 P-valuea
Pain 284 43.9% 813 59.6% <0.001
Intellectual disorder 324 50.1% 481 35.2% <0.001
Mild 61 9.4% 144 10.6% 0.437
Moderate 90 13.9% 138 10.1% 0.012
Severe/profound 135 20.9% 162 11.9% <0.001
Other 214 33.1% 307 22.5% <0.001
Any digestive/bowel disorder 301 46.5% 587 43.0% 0.138
Constipation 158 24.4% 244 17.9% 0.001
Psychosis 195 30.1% 617 45.2% <0.001
Migraine/headache 71 11.0% 411 30.1% <0.001
Depression 40 6.2% 377 27.6% <0.001
Behavioral disorder 164 25.4% 374 27.4% 0.332
Anxiety 48 7.4% 318 23.3% <0.001
Eating disorder 123 19.0% 104 7.6% <0.001
Sleep disorder 106 16.4% 252 18.5% 0.255
Cognitive disorder 58 9.0% 211 15.5% <0.001
ADHD 60 9.3% 173 12.7% 0.026
Walking/gait impairment 74 11.4% 150 11.0% 0.765
Obesity 29 4.5% 134 9.8% <0.001
Arthritis 12 1.9% 132 9.7% <0.001
Stroke/TIA 18 2.8% 96 7.0% <0.001
Notes: ADHD – attention deficit hyperactivity disorder; AED – antiepileptic drug; GI – gastrointestinal; GP – general practitioner; NMDA – N-methyl-D-
aspartate; SD – standard deviation; SVP2a – synaptic vesicle protein 2A; SD – standard deviation; TIA – transient ischemic attack.
a P < 0.05. P-values were obtained using Chi-square tests for categorical variables and t-tests for continuous variables. Fisher’s exact test was used where Chi-
square test was not valid due to cells having fewer than expected counts.
b Other includes aged individual, adult (not based on unemployed status), foster care child, and eligibility status unknown.
c Less than 5% of patients in both cohorts received T-type calcium channel, GABA reuptake inhibitor, barbiturate, carbonic anhydrase inhibitor, and
K-channel opener.
d Less than 5% of patients in both cohorts had a diagnosis of cortical dysplasia, tuberous sclerosis, brain lesions, heart failure, chronic renal disease, and
coronary heart disease.
Bold text indicates a statistically significant difference with a p-value < 0.05.
Table 4. Baseline healthcare utilization of commercial/Medicare Supplemental patients and Medicaid patients.
Commercial/Medicare Supplemental Medicaidb
Clobazam Non-clobazam Clobazam Non-clobazam
N = 590 N = 1384 P-valuea N = 647 N = 1365 P-valuea
Seizure-related health care utilization
Hospitalization, n (%) 217 36.8% 381 27.5% <0.001 209 32.3% 296 21.7% <0.001
Number of inpatient visits, mean (SD) 0.7 (1.3) 0.4 (0.8) <0.001 0.5 (1.1) 0.3 (0.8) <0.001
LOS, mean (SD) 2.6 (7.6) 1.4 (4.7) 0.001 2.2 (6.7) 1.4 (6.0) 0.010
ER visits, n (%) 177 30.0% 418 30.2% 0.929 232 35.9% 539 39.5% 0.118
Number of ER visits, mean (SD) 0.6 (1.3) 0.5 (1.0) 0.216 0.8 (2.0) 0.9 (1.8) 0.365
Physician office visits, n (%) 558 94.6% 1081 78.1% <0.001 577 89.2% 1033 75.7% <0.001
Number of physician office visits, mean (SD) 3.9 (3.5) 2.2 (2.3) <0.001 3.5 (3.2) 2.1 (2.2) <0.001
Neurologist visit, n (%) 347 58.8% 729 52.7% 0.012 60 9.3% 99 7.3% 0.117
Number of neurologist visits, mean (SD) 1.8 (2.2) 1.3 (1.7) <0.001 0.3 (1.1) 0.2 (0.8) 0.024
PCP visit, n (%) 115 19.5% 236 17.1% 0.194 177 27.4% 390 28.6% 0.572
Number of PCP visits, mean (SD) 0.5 (1.6) 0.3 (1.0) 0.010 0.8 (1.8) 0.7 (1.5) 0.304
Laboratory visits, n (%) 254 43.1% 274 19.8% <0.001 163 25.2% 225 16.5% <0.001
Number of laboratory visits, mean (SD) 1.1 (2.2) 0.3 (0.9) <0.001 0.5 (1.2) 0.3 (0.9) <0.001
Radiology visits, n (%) 58 9.8% 110 8.0% 0.170 55 8.5% 113 8.3% 0.866
Number of radiology visits, mean (SD) 0.1 (0.4) 0.1 (0.3) 0.052 0.1 (0.4) 0.1 (0.4) 0.830
Other outpatient visits, n (%) 398 67.5% 640 46.2% <0.001 391 60.4% 588 43.1% <0.001
Number of other outpatient visits, mean (SD) 7.1 (23.2) 1.8 (11.5) <0.001 10.5 (38.3) 4.7 (27.6) 0.001
All-cause healthcare utilization
Hospitalization, n (%) 303 51.4% 708 51.2% 0.935 309 47.8% 614 45.0% 0.243
Number of inpatient visits, mean (SD) 1.1 (1.7) 1.2 (1.8) 0.670 1.0 (1.8) 1.1 (2.0) 0.162
LOS, mean (SD) 5.2 (12.5) 6.5 (18.2) 0.081 5.0 (15.3) 6.7 (19.8) 0.030
ER visits, n (%) 333 56.4% 966 69.8% <0.001 420 64.9% 998 73.1% <0.001
Number of ER visits, mean (SD) 1.6 (2.4) 2.1 (3.2) <0.001 2.3 (3.4) 3.4 (5.2) <0.001
Physician office visits, n (%) 588 99.7% 1361 98.3% 0.016 636 98.3% 1310 96.0% 0.006
Number of physician office visits, mean (SD) 10.9 (7.4) 10.2 (7.6) 0.061 10.7 (7.9) 8.9 (7.2) <0.001
Neurologist visit,b n (%) 378 64.1% 878 63.4% 0.791 67 10.4% 135 9.9% 0.746
Number of neurologist visits, mean (SD) 2.2 (2.5) 1.9 (2.3) 0.010 0.4 (1.5) 0.3 (1.1) 0.082
PCP visit,b n (%) 268 45.4% 852 61.6% <0.001 321 49.6% 712 52.2% 0.286
(Continued )
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Baseline all-cause resource utilization and costs
Commercial/Medicare Supplemental clobazam users had
higher all-cause resource utilization and associated costs,
on average, over the 12-month pre-index period compared
to non-clobazam users (Tables 4 and 5). Higher proportions
of clobazam users had at least one physician office visit
(99.7% vs 98.3%, P = 0.016) and laboratory visit (68.8% vs
62.9%, P = 0.012) any time during the pre-index period
compared to non-clobazamusers. However, the proportion
of patients with at least one all-cause ER visit (56.4% vs
69.8%, P < 0.001) and radiology visit (43.2% vs 55.5%,
P < 0.001) was lower among clobazam users than non-
clobazam users. The average number of neurologist visits
(2.2 ± 2.5 vs 1.9 ± 2.3, P=0.010), laboratory visits (2.3 ± 3.0 vs
1.9 ± 3.0, P = 0.002), and other outpatient visits (33.0 ± 52.3
vs 18.1± 31.3, P<0.001)was higher for clobazamusers than
non-clobazam users. Average annual pre-index all-cause
total ($73,486 ± $110,918 vs $49,632 ± $89,843, P < 0.001),
medical ($58,116 ± $100,102 vs $43,866 ± $86,376,
P < 0.001), and prescription ($15,370 ± $36,617 vs
$5766 ± $18,940, P < 0.001) costs were significantly higher
for clobazam users compared to non-clobazam users.
Overall, Medicaid clobazam users also had higher all-
cause resource utilization and total all-cause costs, on
average, over the 12-month pre-index period compared
to non-clobazam users (Tables 4 and 5).
Table 4. (Continued).
Commercial/Medicare Supplemental Medicaidb
Clobazam Non-clobazam Clobazam Non-clobazam
N = 590 N = 1384 P-valuea N = 647 N = 1365 P-valuea
Number of PCP visits, mean (SD) 2.1 (4.0) 3.2 (4.6) <0.001 3.1 (5.1) 3.4 (5.2) 0.253
Laboratory visits, n (%) 406 68.8% 871 62.9% 0.012 379 58.6% 747 54.7% 0.104
Number of laboratory visits, mean (SD) 2.3 (3.0) 1.9 (3.0) 0.002 1.7 (3.9) 1.8 (3.5) 0.726
Radiology visits, n (%) 255 43.2% 768 55.5% <0.001 254 39.3% 621 45.5% 0.008
Number of radiology visits, mean (SD) 0.9 (1.5) 1.4 (2.9) <0.001 0.7 (1.2) 1.0 (1.7) <0.001
Other outpatient visits, n (%) 567 96.1% 1329 96.0% 0.937 640 98.9% 1335 97.8% 0.082
Number of other outpatient visits, mean (SD) 33.0 (52.3) 18.1 (31.3) <0.001 90.9 (91.4) 63.9 (87.7) <0.001
Notes: ER – emergency room; LOS – length of stay; PCP – primary care physician; SD – standard deviation; USD – United States dollars.
a P < 0.05. P-values were obtained using Chi-square tests for categorical variables and t-tests for continuous variables.
b The majority of claims do not have information on physician specialty.
Bold text indicates a statistically significant difference with a p-value < 0.05.
Table 5. Baseline healthcare costs of commercial/Medicare Supplemental patients and Medicaid patients.
Commercial/Medicare Supplemental Medicaidb
Clobazam Non-clobazam Clobazam Non-clobazam
N = 590 N = 1384 P-valuea N = 647 N = 1365 P-valuea
Annual seizure-related costs in 2014 USD, mean (SD)
Total $33,478 (58,431) $12,709 (36,420) <0.001 $23,219 (84,306) $7687 (25,092) <0.001
Medical $24,066 (56,142) $10,563 (35,194) <0.001 $15,544 (82,673) $5951 (24,374) <0.001
Hospitalization $15,013 (48,020) $7366 (30,951) <0.001 $10,016 (80,795) $4108 (22,651) <0.001
ER $961 (3549) $793 (2314) 0.933 $297 (941) $353 (979) 0.164
Physician office $1581 (3770) $562 (1438) <0.001 $654 (1675) $246 (699) <0.001
Neurologist $384 (577) $214 (363) <0.001 $33 (149) $15 (80) 0.085
PCP $115 (382) $51 (190) 0.077 $66 (183) $53 (247) 0.355
Laboratory $350 (1434) $82 (621) <0.001 $28 (172) $16 (98) <0.001
Radiology $146 (805) $126 (632) 0.138 $57 (375) $43 (212) 0.593
Other outpatient $6015 (22,108) $1634 (11,555) <0.001 $4491 (16,426) $1186 (8086) <0.001
Prescription $9411 (12,416) $2146 (5596) <0.001 $7676 (12,866) $1736 (4262) <0.001
Annual all-cause costs in 2014 USD, mean (SD)
Total $73,486 (110,918) $49,632 (89,843) <0.001 $62,989 (120,325) $38,370 (70,243) <0.001
Medical $58,116 (100,102) $43,866 (86,376) <0.001 $49,667 (105,654) $34,292 (68,737) <0.001
Hospitalization $30,441 (81,555) $24,727 (70,535) 0.168 $17,858 (96,153) $14,498 (58,921) 0.076
ER $3450 (8543) $4671 (9646) <0.001 $1404 (3194) $2036 (4009) <0.001
Physician office $4502 (7071) $2841 (5036) <0.001 $2516 (3508) $1579 (2738) <0.001
Neurologist $483 (681) $344 (524) <0.001 $52 (262) $27 (151) 0.576
PCP $419 (1124) $476 (1275) <0.001 $254 (791) $239 (538) 0.874
Laboratory $679 (1978) $369 (1163) <0.001 $103 (278) $101 (253) 0.038
Radiology $542 (1799) $930 (3911) <0.001 $196 (639) $224 (586) 0.010
Other outpatient $18,500 (40,352) $10,329 (27,363) <0.001 $27,590 (39,437) $15,854 (28,874) <0.001
Prescription $15,370 (36,617) $5766 (18,940) <0.001 $13,321 (45,428) $4078 (7315) <0.001
Notes: ER – emergency room; LOS – length of stay; PCP – primary care physician; SD – standard deviation; USD – United States dollars.
a P < 0.05. P-values for differences in cost were obtained using the Wilcoxon-Mann-Whitney test.
b The majority of claims do not have information on physician specialty.
Bold text indicates a statistically significant difference with a p-value < 0.05.
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Treatment patterns: clobazam and non-clobazam
users
Clinically and statistically significant differences were
observed between the baseline demographic and clin-
ical profiles of clobazam and non-clobazam users.
Therefore, adjustments to ameliorate selection bias
prior to comparison of outcomes were required.
Assessment of the standardized mean differences after
applying the standardized mortality ratio weighting
showed that many of the baseline characteristics
remained unbalanced between the cohorts. Additional
assessments were performed including limiting the
study population and matching on few variables before
the standardized mortality ratio weighting; however,
regardless of method, the baseline characteristics
between the clobazam and non-clobazam cohorts
remained unbalanced (results not shown). Therefore,
no meaningful statistical inference can be drawn on
the comparison of the clobazam and non-clobazam
users, so only univariate analyses were performed and
reported for the assessment of treatment patterns.
Among the Commercial/Medicare Supplemental
population, over the six months post-index, clobazam
users had, on average, 5.5 (±2.6) clobazam prescription
fills and stayed on treatment for an average of 140
(±50.8) days and on all AED treatment for an average
of 166.0 (±29.6) days (Table 6). Non-clobazam users had,
on average, 4.6 (±2.8) index prescription fills and stayed
on index treatment for an average of 119.5 (±62.6) days
and on all AED treatment for an average of 138.4
(±54.0) days over the same post-index period.
Assessment of changes to the index therapy showed
that within the clobazam cohort, 11.4% augmented,
27.5% discontinued, and 56.3% continued clobazam
therapy. Among the non-clobazam users, 9.2% aug-
mented, 38.4% discontinued, and 45.9% continued
their index therapy. Approximately 11.5% of clobazam
users and 33.1% of non-clobazam users discontinued all
AED therapy during the six-month post-index period.
Results over 12-months post-index treatment were con-
sistent with the six-month results.
Among Medicaid patients, clobazam users had, on
average, 5.7 (±2.6) index prescription fills and stayed
on clobazam for an average of 138.7 (±51.5) days and
on any AED for an average of 164.4 (±33.3) days over
the six months of the post-index period (Table 6).
Non-clobazam users had, on average, 4.6 (±2.7)
index prescription fills and stayed on their index
AED for an average of 114.1 (±64.3) days and on any
AED for an average of 134.5 (±56.8) days over the
six months of the post-index period. Assessment of
changes to the index AED showed that among cloba-
zam users, 10.1% augmented, 25.0% discontinued,
and 60.3% continued clobazam therapy. Among the
non-clobazam users, 8.1% augmented, 39.9% discon-
tinued, and 45.6% continued their index AED. Similar
proportions of the clobazam and non-clobazam users
in the Medicaid population discontinued all AED ther-
apy; again, the 12-month results were consistent with
the six-month results.
Healthcare resource utilization and costs:
clobazam: pre- vs post-clobazam treatment
Of the 590 Commercial and Medicare Supplemental
(647 Medicaid) clobazam users, 314 (358 Medicaid)
were continuously enrolled in medical and pharmacy
claims for at least 12 months post-index and had at
Table 6. Treatment patterns of commercial/Medicare Supplemental patients and Medicaid patients.
Commercial/Medicare Supplemental Medicaid
Clobazam Non-clobazam Clobazam Non-clobazam
Treatment Patterns N = 590 N = 1384 N = 647 N = 1365
Number of index AED prescription claims, mean (SD) 5.5 (2.6) 4.6 (2.8) 5.7 (2.6) 4.6 (2.7)
Total days on index AED, mean (SD) 140.1 (50.8) 119.5 (62.6) 138.7 (51.5) 114.1 (64.3)
Changes to index treatment, n (%)
Augmentation 67 11.4% 127 9.2% 65 10.1% 111 8.1%
Switching 29 4.9% 91 6.6% 30 4.6% 86 6.3%
Discontinuation 162 27.5% 531 38.4% 162 25.0% 545 39.9%
Continued index therapy 332 56.3% 635 45.9% 390 60.3% 623 45.6%
Time to change in index treatment in days, mean (SD)
Time to augmentation 60.8 (50.2) 49.6 (55.6) 70.6 (58.0) 59.3 (63.1)
Time to switch 76.2 (50.9) 69.0 (51.0) 99.4 (47.0) 59.0 (46.1)
Time to discontinuation 60.4 (36.8) 47.9 (35.4) 55.0 (33.6) 45.1 (36.9)
Total days on any AED,a mean (SD) 166.0 (29.6) 138.4 (54.0) 164.4 (33.3) 134.5 (56.8)
All AEDa discontinuation rate, n (%) 68 11.5% 458 33.1% 72 11.1% 462 33.8%
Time to discontinuation from all AEDsa in days, mean (SD) 71.4 (37.9) 52.3 (36.6) 62.4 (35.0) 49.5 (38.3)
Notes: AED – antiepileptic drug; SD – standard deviation.
a Eight AEDs were considered in the study.
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least one clobazam prescription between 6 and
12 months post-index. Seizure-related and all-cause
healthcare utilization data for the 12-month pre- and
post-clobazam initiation periods are presented in
Figures 2–5, while associated costs are presented in
Table 7.
Seizure-related resource utilization and costs
The proportions of patients hospitalized (38.2% vs
30.9%, P = 0.032) and receiving ER care (31.9% vs
18.5%, P < 0.001) post-clobazam initiation were lower
compared with the period prior to clobazam initiation
among the Commercial and Medicare Supplemental
population (Figure 2). The mean numbers of seizure-
related inpatient stays (0.7 ± 1.3 vs 0.5 ± 1.1, P = 0.008),
ER visits (0.7 ± 1.4 vs 0.4 ± 1.2, P < 0.001), and neurol-
ogist visits (2.0 ± 2.3 vs 1.7 ± 2.0, P = 0.011) were also
significantly lower post-clobazam initiation (Figure 3).
Finally, the mean number of unique concomitant AED
agents (excluding clobazam) decreased post-clobazam
initiation (1.7 ± 1.1 vs 1.5 ± 1.0, P < 0.001).
Average annual seizure-related medical costs were
significantly lower post-clobazam initiation
($23,740 ± $52,288 vs $19,958 ± $43,090, P = 0.004),
driven by lower seizure-related ER ($908 ± $2612 vs
$662 ± $3441, P = 0.002) and physician office visit
($1873 ± $4673 vs $1278 ± $1981, P = 0.005) costs
(Table 7). However, there were significantly higher
seizure-related prescription costs in the post-index
period ($9549 ± $12,578 vs $15,125 ± $13,735,
P < 0.001), which resulted in significantly higher aver-
age annual seizure-related total costs compared to
before initiation ($33,289 ± $54,938 vs
$35,083 ± $46,149, P = 0.029).
Among Medicaid patients, similar trends in seizure-
related resource utilization and costs were observed over
the 12 months post-clobazam initiation compared to pre-
clobazam initiation. However, while the proportion of














































































































Figure 2. Proportion of patients utilizing seizure-related healthcare resources pre- vs post-clobazam.
Notes: ER – emergency room; PCP – primary care physician. P-values in bold < 0.05. P-values for unadjusted differences in
categorical variables were obtained using McNemar’s test to account for pre-post design.
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utilization for other outpatient services significantly
increased post-clobazam initiation. Also in this population,
the reduction in medical costs was driven predominantly
by a reduction in seizure-related hospitalization costs.
All-cause resource utilization and costs
In the 12 months following clobazam initiation, there
were no significant differences in the proportions of
Commercial and Medicare Supplemental patients with
all-cause resource utilization in specific settings com-
pared with the 12 months prior to clobazam initiation
(Figure 4). The mean number of neurologist visits
(2.4 ± 2.5 vs 2.0 ± 2.2, P = 0.003) and PCP visits over
12 months significantly decreased (2.1 ± 4.1 vs
1.7 ± 3.2, P = 0.009) post-clobazam initiation compared
with pre-clobazam initiation, while the number of
other outpatient visits increased (33.4 ± 53.4 vs
38.9 ± 60.9, P = 0.004) (Figure 5).
Average annual all-cause medical costs were not
significantly different post-clobazam initiation
($57,090 ± $107,206 vs $59,292 ± $93,302, P = 0.411)
(Table 7). However, there were significantly higher all-
cause prescription costs post-clobazam initiation
($16,229 ± $35,832 vs $22,098 ± $44,556, P < 0.001),
resulting in significantly higher average annual all-cause
total costs compared to pre-clobazam initiation
($73,319 ± $117,534 vs $81,389 ± $110,776, P < 0.001).
Among Medicaid patients, the proportion of
patients with at least one hospitalization and neurol-


























































































































P=0.040 P=0.202 P=0.760 P=0.633
P=0.027
P<0.001
Figure 3. Mean number of seizure-related healthcare services utilized pre- vs post-clobazam.
Notes: AED – antiepileptic drug; ER – emergency room; PCP – primary care physician. P-values in bold < 0.05. P-values for count
variables were obtained using paired t-tests to account for pre-post design. *Includes clobazam.
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clobazam initiation. Post-clobazam initiation, the
average number of ER visits, physician office visits,
and neurologist visits decreased, while the number of
other outpatient visits increased compared to pre-
clobazam. The all-cause costs trend from the pre-
clobazam period to the post-clobazam period was
similar to that for the Commercial and Medicare
Supplemental patients.
Discussion
This study demonstrated that there are key differences
in the demographic and clinical characteristics of prob-
able LGS patients initiating treatment with clobazam
compared to those initiating other AEDs in both the
Commercial/Medicare Supplemental and Medicaid
populations under study. Treatment patterns associated
with the index AED and overall AED use also differed
between these patients. In addition, among patients
treated with clobazam, both seizure-related healthcare
utilization and its associated medical costs declined
when compared to an equivalent 12-month period
prior to treatment initiation.
Patients who initiated treatment with clobazam were
younger and received more seizure-related clinical care
prior to treatment initiation than those who initiated
treatment with alternative AEDs. Prior to treatment initia-
tion, clobazam patients also had higher seizure-related
healthcare utilization and incurred both higher all-cause
and seizure-related costs compared to those treated with
other AEDs. Results were presented for the overall popu-
lation due to the similar trend observed when clobazam
and non-clobazam patients were compared in pediatric
and adult cohorts (analysis not presented).
Several statistical methods were employed in an
attempt to create comparability between the baseline
characteristics of the clobazam and non-clobazam
cohorts; however, none were successful. These results
highlight that LGS patients enrolled in this sample of
employer-sponsored andMedicaid benefit plans and initi-
ating clobazam treatment compared to other AED treat-
ments during the same time period have greater disease
severity, which suggests a physician prescribing prefer-
ence for clobazam in LGS patients who have more severe
epilepsy. Similar findings were observed in a database
study conducted in adult epilepsy patients in the United
Kingdom (UK). In that study, prior to treatment initiation,
Table 7. Pre-index and post-index healthcare costs among clobazam patients in the commercial/Medicare Supplemental and
Medicaid populations.
Commercial/Medicare Supplemental
(N = 314) Medicaid (N = 358)
Pre-clobazam Post-clobazam P-valuea Pre-clobazam Post-clobazam P-valuea
Healthcare costs
Annual seizure-related costs in 2014 USD, mean
(SD)
Total $33,289 (54,938) $35,083 (46,149) 0.029 $27,541 (109,816) $28,493 (44,016) <0.001
Medical $23,740 (52,288) $19,958 (43,090) 0.004 $18,965 (108,221) $14,442 (39,754) 0.036
Hospitalization $13,711 (41,266) $11,639 (32,128) 0.094 $12,608 (106,674) $7805 (35,724) 0.006
ER $908 (2612) $662 (3441) 0.002 $304 (892) $196 (502) 0.003
Physician office $1873 (4673) $1278 (1981) 0.005 $728 (1422) $657 (1485) 0.001
Neurologist $448 (672) $355 (508) 0.022 $30 (142) $17 (77) 0.100
PCP $116 (391) $81 (298) 0.072 $76 (212) $65 (194) 0.303
Laboratory $397 (1385) $270 (1026) 0.177 $34 (226) $46 (324) 0.378
Radiology $124 (689) $92 (476) 0.366 $58 (436) $29 (181) 0.336
Other outpatient $6727 (25,573) $6018 (20,393) 0.733 $5234 (17,472) $5708 (17,619) 0.263
Prescription $9549 (12,578) $15,125 (13,735) <0.001 $8576 (14,445) $14,051 (16,375) <0.001
Annual all-cause costs in 2014 USD, mean (SD)
Total $73,319 (117,534) $81,389 (110,776) <0.001 $68,565 (150,749) $73,153 (102,307) <0.001
Medical $57,090 (107,206) $59,292 (93,302) 0.411 $52,667 (131,965) $52,937 (89,727) 0.880
Hospitalization $28,079 (84,526) $29,097 (57,815) 0.308 $20,860 (124,848) $18,809 (70,923) 0.506
ER $3228 (7792) $3128 (9189) 0.102 $1382 (2714) $1194 (2122) 0.421
Physician office $4984 (8060) $4243 (5961) 0.076 $2596 (3365) $2431 (3329) 0.024
Neurologist $546 (763) $457 (686) 0.013 $50 (290) $23 (113) 0.055
PCP $456 (1317) $311 (777) 0.060 $235 (447) $236 (423) 0.509
Laboratory $725 (1965) $580 (1525) 0.294 $111 (333) $130 (516) 0.309
Radiology $471 (1467) $341 (978) 0.214 $203 (715) $131 (404) 0.028
Other outpatient $19,603 (47,316) $21,903 (48,312) 0.073 $27,516 (37,829) $30,242 (40,282) 0.092
Prescription $16,229 (35,832) $22,098 (44,556) <0.001 $15,898 (58,577) $20,215 (36,680) <0.001
Notes: ER – emergency room; PCP – primary care physician; SD – standard deviation; USD – United States dollars.
a P-values in bold <0.05. P-values for unadjusted differences in categorical variables were obtained using McNemar’s test to account for pre-post design.
Similarly, P-values for count variables were obtained using paired t-tests. P-values for difference in mean costs were obtained using Wilcoxon signed-rank
test (non-parametric version of a paired t-test) and P-values for difference in median costs were obtained using Wilcoxon signed rank test.
Bold text indicates a statistically significant difference with a p-value < 0.05.
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patients initiating clobazam treatment were younger and
had greater use of concomitant AEDs than those receiving
clonazepam [15].
Treatment pattern results were not statistically com-
pared between the clobazam and non-clobazam
cohorts due to the differences described; however, the
unadjusted results indicate that patients treated with
clobazam discontinued or switched treatment less
often and stayed on treatment longer relative to
patients initiating treatment with alternative AEDs. The
lower rate of treatment discontinuation and switch
among the clobazam users may be due to better treat-
ment benefit with clobazam, resulting in patients
remaining on treatment longer. Adverse events profile
of these drugs might have also affected the rate of
treatment discontinuation and switch. Treatment pat-
terns in LGS patients have not been extensively evalu-
ated; although in the UK study noted above, treatment
duration differed from that reported in the current
study [15]. The median treatment duration was similar
between the epilepsy patients treated with clobazam or
clonazepam. The observed differences could be a result
of the duration of follow-up; the current study evalu-
ated treatment patterns over both a 6- and 12-month
period, while average follow-up in the UK study was at
least five years.
Among patients treated with clobazam, healthcare
resource utilization and its associated costs were com-
pared among clobazam users at 12 months pre- and
post-clobazam initiation. Results showed that all-cause
and seizure-related resource utilization was significantly
reduced post-clobazam initiation. Higher prescription
costs post-clobazam initiation was mostly offset by the
reduction in medical costs, due in part to a reduction in
seizure-related hospitalizations and ER visits. These
results are also consistent with previous findings that
clobazam could have a positive overall economic impact
















































































































Figure 4. Proportion of patients utilizing all-cause healthcare resources pre- vs post-clobazam.
Notes: ER – emergency room; PCP – primary care physician. P-values in bold < 0.05. P-values for unadjusted differences in
categorical variables were obtained using McNemar’s test to account for pre-post design.
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In addition to decreased seizure-related medical costs,
clobazam may also have an impact on indirect costs,
such as decreased caregiver time, resulting in less pro-
ductivity loss, and decreased long-term disability due to
head injury for children [16].
This study has inherent limitations due to the use of
claims data. There is no specific ICD-9-CM diagnosis
code for LGS, and while the patient identification algo-
rithm used in this investigation was based on pre-
viously published criteria and clinical opinion,
misclassification of LGS patients might still be present.
However, our results still provide valuable insight into
the use of AED and impact of clobazam on costs in LGS
patients. Baseline characteristics of clobazam and non-
clobazam users indicate that these are patients with
different disease severity, and statistical methods
employed to remove these differences were
unsuccessful. As a result, differences in post-index mea-
sures could not be evaluated between the clobazam
and non-clobazam cohorts. Furthermore, clinical data
are unavailable in the database; therefore, clinical
observations that might influence physicians to pre-
scribe one AED vs another could not be evaluated,
and instead proxy measures of baseline disease severity
and comorbidity were used. Another limitation is the
pre- and post-treatment design, which has a potential
for regression to the mean effect. However, this bias is
more likely to occur when there is a treatment switch
during an acute episode, such as in schizophrenia [17],
than in the case of LGS, a chronic condition in which
clobazam is often added to existing treatments. Finally,
since the analysis focused on burden specific to medical
resource use, it provides no insight into the relative
impact of clobazam and other AEDs with respect to
1.1 1.6
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P=0.015 P=0.725 P=0.837 P=0.750
P<0.001
Figure 5. Mean number of all-cause healthcare services utilized pre- vs post-clobazam.
Notes: ER – emergency room; PCP – primary care physician. P-values in bold < 0.05. P-values for count variables were obtained
using paired t-tests to account for pre-post design.
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clinically important outcomes such as patient quality of
life, activities of daily living, and caregiver burden.
Conclusions
Baseline comparisons suggest a prescribing prefer-
ence for clobazam in LGS patients with more severe
disease, regardless of whether the patient has health-
care benefits provided through private or public
payers. The inability to eliminate selection bias
further emphasizes the differences between the clo-
bazam and non-clobazam treated cohorts. Regardless,
clobazam users did have significant improvement in
seizure-related resource utilization and medical costs
post-clobazam initiation compared to the year prior
to clobazam initiation.
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